References
1. Murayama A, Kamamoto S, Shigeta H, Ozaki A. Industry Payments During the COVID-19 Pandemic to Cardiologists in the United States. CJC Open 2023;5(3):253-255.
2. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA. Types and Distribution of Payments From Industry to Physicians in 2015. JAMA 2017;317(17):1774-1784.
3. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of Industry Payments to Physicians: An Epidemiologic Analysis of Early Data From the Open Payments Program. Mayo Clin Proc 2016;91(1):84-96.
4. Murayama A. Industry-sponsored meal payments are associated with prescriptions and Medicare expenditures on brand-name colchicine in the United States. International Journal of Rheumatic Diseases 2023;n/a(n/a).
5. Murayama A. Pharmaceutical industry-sponsored meals and prescriptions of biologics for asthma. J Allergy Clin Immunol Pract 2023;11(9):2916-2918.
6. Mitchell AP, Dusetzina SB, Mishra Meza A, Trivedi NU, Bach PB, Winn AN. Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study. Bmj 2023;383:e075512.
7. Mitchell AP, Trivedi NU, Gennarelli RL, et al. Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review. Ann Intern Med 2021;174(3):353-361.
8. Annapureddy AR, Henien S, Wang Y, et al. Association Between Industry Payments to Physicians and Device Selection in ICD Implantation. Jama 2020;324(17):1755-1764.
9. Yanagisawa M, Blumenthal DM, Kato H, Inoue K, Tsugawa Y. Associations Between Industry Payments to Physicians for Antiplatelet Drugs and Utilization of Cardiac Procedures and Stents. J Gen Intern Med 2022;37(7):1626-1633.
10. Medical Governance Research Institute, Tansa. Yen For Docs. Medical Governance Research Institute; 2023.
11. Murayama A, Saito H, Kamamoto S, Shigeta H, Yamashita E, Tanimoto T, Ozaki A. Evaluation of non-research payments from pharmaceutical companies to urologists in Japan between 2016 and 2019. Int Urogynecol J 2023;34(6):1285-1292.
12. Murayama A, Saito H, Tanimoto T, Ozaki A. Financial conflicts of interest between pharmaceutical companies and executive board members of internal medicine subspecialty societies in Japan between 2016 and 2020. J Eval Clin Pract 2023;29(6):883-886.
13. Murayama A, Mamada H, Shigeta H, et al. Financial Relationships Between Pharmaceutical Companies and Rheumatologists in Japan Between 2016 and 2019. J Clin Rheumatol 2023;29(3):118-125.
14. Murayama A, Hoshi M, Saito H, et al. Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019. Respiration 2022;101(12):1088-1098.
15. Kamamoto S, Ozaki A, Murayama A. Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019. Cureus 2023;15(8):e43633.
16. Murayama A, Kamamoto S, Saito H, Ozaki A. Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Sci Rep 2023;13(1):7425.
17. Kusumi E, Murayama A, Kamamoto S, et al. Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019. Blood Cancer J 2022;12(4):54.
18. Senoo Y, Saito H, Ozaki A, et al. Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension. Medicine (Baltimore) 2021;100(12):e24816.
19. Murayama A, Kamamoto S, Kawashima M, Saito H, Yamashita E, Tanimoto T, Ozaki A. Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019. BMJ Open 2023;13(4):e068237.
20. Annapureddy A, Murugiah K, Minges KE, Chui PW, Desai N, Curtis JP. Industry Payments to Cardiologists. Circ Cardiovasc Qual Outcomes 2018;11(12):e005016.
21. Murayama A, Kamamoto S, Kugo H, Saito H, Ozaki A. Research and Nonresearch Industry Payments to Nephrologists in the United States between 2014 and 2021. J Am Soc Nephrol 2023;34(10):1709-1720.
22. Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A 9-Year Investigation of Healthcare Industry Payments to Pulmonologists in the United States. Ann Am Thorac Soc 2023;20(9):1283-1292.
23. Kamamoto S, Murayama A, Kusumi E, et al. Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross-sectional analysis of personal payments from pharmaceutical companies between 2016 and 2019. Pediatr Blood Cancer 2022;69(10):e29891.
24. Murayama A, Shigeta H, Kamamoto S, et al. Pharmaceutical Payments to Japanese Board-Certified Head and Neck Surgeons Between 2016 and 2019. OTO Open 2023;7(1):e31.
25. Murayama A, Kamamoto S, Saito H, et al. Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019. Int J Environ Res Public Health 2022;19(12):7417.
26. Muluk SL, Lin GA, Anderson TS. Association of Device Industry Payments, Physician Supply, and Regional Utilization of Orthopedic and Cardiac Procedures. Journal of General Internal Medicine 2023;38(11):2501-2510.
27. Fleischman W, Agrawal S, King M, et al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ 2016;354:i4189.
28. Murayama A, Kamamoto S, Murata N, et al. Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines. J Gastroenterol Hepatol 2023;38(4):565-573.
29. Mamada H, Murayama A, Ozaki A, et al. Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019. Medicine (Baltimore) 2023;102(4):e32776.
30. Murayama A, Yamada K, Yoshida M, et al. Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline. Clin J Am Soc Nephrol 2022;17(6):819-826.
31. Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T, Akihiko O. Undisclosed financial conflicts of interest with pharmaceutical companies among the authors of the Esophageal Cancer Practice Guidelines 2017 by the Japan Esophageal Society. Dis Esophagus 2022;35(10).
32. Harada K, Ozaki A, Saito H, et al. Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017. Health Policy 2021;125(3):320-326.
33. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T. Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment. Liver Int 2021;41(3):464-469.
34. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A. Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan. Clin Microbiol Infect 2022;28(3):460-462.
35. Murayama A, Ozaki A, Saito H, Sawano T, Sah R, Tanimoto T. Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies. Clin Microbiol Infect 2020;27(5):805-807.
36. Murayama A. Financial Conflicts of Interest Among the Authors of the Clinical Practice Guidelines for Rheumatoid Arthritis in Japan. Cureus 2023;15(10):e46650.
37. Mamada H, Murayama A, Kamamoto S, et al. Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors’ Self-Citation Rate in Japan and the United States. Arthritis Care Res (Hoboken) 2023;75(6):1278-1286.
Table 1. Summary of personal payments to board-certified cardiologists